Aptose Biosciences Inc. (TSE:APS – Get Free Report) (NASDAQ:APTO) was up 52.1% on Friday . The company traded as high as C$0.55 and last traded at C$0.37. Approximately 206,079 shares were traded during trading, an increase of 1,572% from the average daily volume of 12,326 shares. The stock had previously closed at C$0.24.
Aptose Biosciences Price Performance
The company has a debt-to-equity ratio of 670.80, a current ratio of 0.80 and a quick ratio of 5.41. The stock has a market capitalization of C$6.97 million, a PE ratio of -0.07 and a beta of 1.36. The firm’s 50 day simple moving average is C$0.41 and its 200 day simple moving average is C$0.66.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Further Reading
- Five stocks we like better than Aptose Biosciences
- What is the Shanghai Stock Exchange Composite Index?
- Opal Fuels CEO on Steering the Future of Renewable Natural Gas
- How to Read Stock Charts for Beginners
- MicroStrategy Joins Nasdaq-100: 2 Crypto Stocks Set to Win
- CD Calculator: Certificate of Deposit Calculator
- 2 Underrated Quantum Computing Companies Starting to Rally
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
